Revive Therapeutics announces results of annual shareholder meeting

Revive Therapeutics (RVVTF) announced the voting results for its annual and special meeting of shareholders that was held on Tuesday, March 18, 2025. At the Meeting, shareholders elected the following nominees to the board of directors: Michael Frank, CeO; Joshua Herman, Independent Director; Andrew Lindzon, Independent Director; William Jackson, Independent Director; Christian Scovenna, Independent Director. Shareholders also approved: The appointment of Horizon Assurance, Chartered Professional Accountants, as the auditor of the Company for the ensuing fiscal year; Authorization for the directors to fix the remuneration paid to the auditor; A resolution authorizing the continuation of Company’s 10% rolling incentive stock option plan for the ensuing year. In light of feedback from shareholders, the Board of Directors decided not to proceed with the proposal to amend of the Company’s articles of incorporation to consolidate its outstanding Common Shares.